Study of Yellow Fever Vaccine Responses in Brazil
Author Information
Author(s): de Melo Andréa Barbosa, Maria da Paz C. Magalhães, Maria Cecília F. Gonzales Gil, Laura Helena Vega Freese de Carvalho, Eduardo M. Braga-Neto, Ulisses M. Bertani, Giovani Rota Marques, Ernesto T. A. Marques Jr., Marli Tenório Cordeiro
Primary Institution: Aggeu Magalhães Research Center, Fiocruz, Recife, Pernambuco, Brazil
Hypothesis
Does previous exposure to dengue virus affect the immune response to the yellow fever vaccine?
Conclusion
The yellow fever 17DD vaccine induces strong and long-lasting immunity, with 100% seroconversion observed in the study cohort.
Supporting Evidence
- 70.6% of vaccinated individuals developed anti-YF IgM antibodies.
- 98.3% of vaccinated individuals developed anti-YF IgG antibodies.
- 100% of individuals developed a protective immune response as measured by PRNT.
- Previous exposure to dengue did not significantly affect the immune response to the yellow fever vaccine.
Takeaway
The yellow fever vaccine helps people build strong defenses against the virus, and most people stay protected for a long time after getting the shot.
Methodology
A prospective study with blood samples collected from individuals vaccinated with the yellow fever 17DD vaccine over a period of 5 years.
Potential Biases
Potential bias due to self-reported health status and the exclusion of individuals who could not provide follow-up samples.
Limitations
The study had a small sample size and excluded some participants due to follow-up issues.
Participant Demographics
Participants were healthy individuals aged 10 years and older, with a median age of 32 years; 36.1% were female.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI = 744–3096
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website